Drug shows promise for Ebola virus treatment in primates

December 11, 2003

For the first time, scientists have successfully treated monkeys infected with the deadly Ebola virus. Ebola causes hemorrhagic fever that kills up to 80 percent of humans infected with the virus.

These findings, published in the December 13th issue of THE LANCET, represent an important step in the search for a treatment strategy for Ebola. Currently no effective therapies are available.

In the study, Thomas W. Geisbert and colleagues from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) injected 12 rhesus macaques with Ebola virus. Nine of the animals received a drug called recombinant nematode anticoagulant protein c2 (rNAPC2), while the remaining three were untreated.

In the treatment group, monkeys received rNAPC2 either immediately after Ebola infection, or 24 hours later, and continued to receive it daily for up to fourteen days. Three of the nine monkeys survived, and death was slowed by several days in the remaining six. All three untreated animals died.

Previous attempts to use antiviral drugs to treat Ebola have demonstrated success in mice and guinea pigs, but not in primates. Geisbert's team approached the problem a different way--by focusing on the symptoms triggered by the virus, rather than the virus itself.

Ebola causes coagulopathy, or abnormal blood clotting, which ultimately leads to massive hemorrhage and death. Studies at USAMRIID suggest that macrophages, a type of white blood cell, play an important role in this process. When a host is infected with Ebola virus, the macrophages express a clotting protein, called tissue factor, on their surfaces. These cells are then attracted to the blood as it flows through the body, forming localized clots that pave the way for abnormal bleeding.

Using rNAPC2, according to Geisbert, essentially blocks the harmful effects of tissue factor. The drug is already being evaluated to treat coronary problems, and has a demonstrated pharmacokinetic and safety profile in humans.

"Our results have potentially important clinical implications, since our treatment approach targets the disease process rather than replication of the Ebola virus," he said. "Moreover, our findings raise the possibility that rNAPC2 could be useful in the treatment of other viral hemorrhagic fevers. The next step will be to test clinical efficacy of this treatment modality in persons at risk for the disease."

Erik A. Henchal, commander of USAMRIID, commented that Institute scientists continually develop and evaluate a full spectrum of medical products to counter highly hazardous diseases.

"This promising research demonstrates our commitment to efficiently leverage products developed in the pharmaceutical industry and apply them to military and public health problems with our federal partners in the Department of Health and Human Services," he said. "The discovery of this drug adds to our armamentarium of candidate vaccines and medical diagnostics that can be used to limit the public health impact of hemorrhagic fevers."

Study collaborators were Lisa E. Hensley, Peter B. Jahrling, Tom Larsen, Joan B. Geisbert, and Jason Paragas of USAMRIID; Howard A. Young of the National Cancer Institute; Terry M. Fredeking of Antibody Systems; and William E. Rote and George P. Vlasuk of Corvas International.
-end-
USAMRIID, located at Fort Detrick, Maryland, is the lead laboratory for the Medical Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

US Army Medical Research Institute of Infectious Diseases

Related Ebola Articles from Brightsurf:

Targeting the shell of the Ebola virus
As the world grapples with COVID-19, the Ebola virus is again raging.

Why doesn't Ebola cause disease in bats, as it does in people?
A new study by researchers from The University of Texas Medical Branch at Galveston uncovered new information on why the Ebola virus can live within bats without causing them harm, while the same virus wreaks deadly havoc to people.

Ebola transmission risks would be taken more seriously with ground-up interventions
A study led by the University of Kent's Durrell Institute of Conservation and Ecology (DICE) has found significant differences in disease risk perception and channels of information about Ebola virus disease (EVD) in rural areas and urban centres of Guinea, West Africa.

US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

Ebola antibodies at work
Scientists in Israel and Germany show, on the molecular level, how an experimental vaccine offers long-term protection against the disease.

Half of Ebola outbreaks undetected
An estimated half of Ebola virus disease outbreaks have gone undetected since it was discovered in 1976, according to research published in PLOS Neglected Tropical Diseases.

Protecting those on the frontline from Ebola
Online training developed at the Medical University of South Carolina (MUSC) increased the knowledge of health care workers about effective prevention of Ebola up to 19 percent and reduced critical errors to 2.3 percent in a small MUSC cohort.

Another piece of Ebola virus puzzle identified
A team of researchers have discovered the interaction between an Ebola virus protein and a protein in human cells that may be an important key to unlocking the pathway of replication of the killer disease in human hosts.

How the human immune system protects against Ebola
'The current approach for treatment of filovirus infections with antibody cocktails tested in animal models utilizes the principle of targeting of non-overlapping epitopes.

How to slow down Ebola
The phylogenetic tree of the 2013-2016 Ebola epidemic doesn't just tell us how the Ebola virus was able to evolve: it also reveals which events and preventive measures accelerated or slowed down its spread.

Read More: Ebola News and Ebola Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.